Skip to main content
Figure 1 | Molecular Cancer

Figure 1

From: Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1α

Figure 1

Cancer cell lines with wild-type or tyrosine kinase domain-mutated EGFR. (a) PCR fragments from the indicated cell lines were compared with the wild-type sequence of EGFR. The black arrows indicate the codons E746 to A750, which are present in the EGFR in DiFi cells but have been deleted in HCC827 and HCC2279 cells. Codon L858R substitution in H1975 and H3255 cells is indicated by arrows. (b) Lysates from the indicated cell lines maintained in regular culture medium were prepared for Western blot analysis using antibodies directed against EGFR, HER2, and HER3, and antibodies directed against total and activation-specific phosphorylated downstream signaling molecules (ERK, Akt, and STAT3). The level of β-actin was used as a reference of lysate protein loading control of each cell line.

Back to article page

Molecular Cancer

ISSN: 1476-4598